ClinicalTrials.gg
RecruitingNCT07605221Updated May 22, 2026

Nomogram for Astigmatism Correction of KLEx

An interventional study of nomogram in Astigmatism, sponsored by Tianjin Eye Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Tianjin Eye Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Feb 2025, registered May 2026).
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Astigmatism with a site in China — 11 open to participants now, 13 under way, none of them phase 3. Astigmatism · China.

Planned enrollment
8th of 17
100 · median 100
Started
2025
with 3 others
No phase
16 of 29
6 open now
Primary completion
2026-12
later than 9 of 12 live
Registered
28th of 29
by date
Lead sponsor
5 of 29
Tianjin Eye Hospital

Among the 29 studies in Astigmatism with a site in China, this one is the 8th largest by planned enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2025, is one of 16 with no phase, reaches primary completion later than 9 of the 12 other live ones, and was the 28th registered.

Astigmatism

418 studies on the registry are indexed under Astigmatism; 51 are open to participants now.

Browse Astigmatism studies →

Open to participants now

11 of the 29 studies in Astigmatism with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 32 Astigmatism studies recruiting now, 12 (38%) set no upper age limit and 15 (47%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Astigmatism with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if nomogram could promote treatment outcomes in astigmatism correction. The main question it aims to answer is:

does the nomogram could promote treatment outcomes in astigmatism correction? If there is a comparison group: Researchers will compare non-nomogram adopted to see if the outcome acceptable.

Participants will ask to complete 3-month follow-up of manifest refraction and visual acuity test.

03

Conditions studied

  • Astigmatism

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age ≥18 years; preoperative sphere -0.50 D to -10.00 D; preoperative cylinder -1.50 D to -5.00 D; stable refraction (±0.50 D) for 1 year; normal corneal topography; central corneal thickness >500 μm or predicted residual stromal bed >280 μm; intraocular pressure \<21 mmHg

Exclusion criteria

Exclusion Criteria:

  • ocular or systematic disease
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    nomogram group

    astigmatism was corrected with nomogram adjustment

    Procedure: nomogram

  • No intervention
    control group

    astigmatism was corrected without nomogram adjustment

Interventions

  • Procedurenomogram

    nomogram was added to nomogram group

06

What researchers measure

Primary outcomes

  1. residual astigmstism

    Time frame: 3 months

Secondary outcomes

  1. visual acuity

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

Of 77 non-industry interventional studies with no phase under Astigmatism, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 22 months is above that.

Counting every sponsor, half of 183 studies reached it within 12 months; a quarter within 4 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
May 22, 2026
StartActual
Feb 18, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07605221
Lead sponsor
Tianjin Eye Hospital
Responsible party
Sponsor
First posted
May 22, 2026
Start date
Feb 18, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 22, 2026

Study contacts

Jiamei Zhang
Contact
jiamei3536@163.com
022-27305083

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion